Current Options in Antifungal Pharmacotherapy
The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
Infections caused by yeasts and molds continue to be associated with high rates of morbidity and mortality in both immunocompromised and immunocompetent patients. Many antifungal drugs have been developed over the past 15 years to aid in the management of these infections. However, treatment is still not optimal, as the epidemiology of the fungal infections continues to change and the available antifungal agents have varying toxicities and drug‐interaction potential. Several investigational antifungal drugs, as well as nonantifungal drugs, show promise for the management of these infections.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Voriconazole versus Amphotericin B for Primary Therapy of Invasive Aspergillosis
Herbrecht, R., Denning, D. W., Patterson, T. F., Bennett, J. E., Greene, R. E., Oestmann, J.-W., Kern, W. V., Marr, K. A., Ribaud, P., Lortholary, O., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020191 · Cited by 3,304
2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer
Hughes, W. T., Armstrong, D., Bodey, G. P., Bow, E. J., Brown, A. E., Calandra, T., Feld, R., Pizzo, P. A., Rolston, K. V. I., Shenep, J. L., et al. (2002) · Clinical Infectious Diseases · doi:10.1086/339215 · Cited by 1,964
Guidelines for Treatment of Candidiasis
Pappas, P. G., Rex, J. H., Sobel, J. D., Filler, S. G., Dismukes, W. E., Walsh, T. J., & Edwards, J. E. (2004) · Clinical Infectious Diseases · doi:10.1086/380796 · Cited by 1,440 · cited 6×
“In fact, doses of fluconazole have increased from 50 mg/day in initial clinical trials to 400–800 mg/day routinely used for invasive candidiasis.(6) Most adverse effects experienced with fluconazole are minor (usually gastrointestinal) and rarely lead to discontinuation of therapy.”
BackgroundResultInfluentialComparison of Caspofungin and Amphotericin B for Invasive Candidiasis
Mora-Duarte, J., Betts, R., Rotstein, C., Colombo, A. L., Thompson-Moya, L., Smietana, J., Lupinacci, R., Sable, C., Kartsonis, N., & Perfect, J. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021585 · Cited by 1,380
Clinical, Cellular, and Molecular Factors That Contribute to Antifungal Drug Resistance
White, T. C., Marr, K. A., & Bowden, R. A. (1998) · Clinical Microbiology Reviews · doi:10.1128/cmr.11.2.382 · Cited by 1,353
Morrell, M., Fraser, V. J., & Kollef, M. H. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.9.3640-3645.2005 · Cited by 1,286
Liposomal Amphotericin B for Empirical Therapy in Patients with Persistent Fever and Neutropenia
Walsh, T. J., Finberg, R. W., Arndt, C., Hiemenz, J., Schwartz, C., Bodensteiner, D., Pappas, P., Seibel, N., Greenberg, R. N., Dummer, S., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903113401004 · Cited by 1,205
Garey, K. W., Rege, M., Pai, M. P., Mingo, D. E., Suda, K. J., Turpin, R. S., & Bearden, D. T. (2006) · Clinical Infectious Diseases · doi:10.1086/504810 · Cited by 1,171
Rex, J. H., Bennett, J. E., Sugar, A. M., Pappas, P. G., van der Horst, C. M., Edwards, J. E., Washburn, R. G., Scheld, W. M., Karchmer, A. W., Dine, A. P., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199411173312001 · Cited by 1,039
Walsh, T. J., Pappas, P., Winston, D. J., Lazarus, H. M., Petersen, F., Raffalli, J., Yanovich, S., Stiff, P., Greenberg, R., Donowitz, G., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejm200201243460403 · Cited by 979
Anidulafungin versus Fluconazole for Invasive Candidiasis
Reboli, A. C., Rotstein, C., Pappas, P. G., Chapman, S. W., Kett, D. H., Kumar, D., Betts, R., Wible, M., Goldstein, B. P., Schranz, J., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066906 · Cited by 894 · cited 2×
“3%).(236) These findings were not significantly different from those seen with the comparator.”
MethodResultPizzo, P. A., Robichaud, K. J., Gill, F. A., & Witebsky, F. G. (1982) · The American Journal of Medicine · doi:10.1016/0002-9343(82)90594-0 · Cited by 859
Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis
Denning, D. W., Ribaud, P., Milpied, N., Caillot, D., Herbrecht, R., Thiel, E., Haas, A., Ruhnke, M., & Lode, H. (2002) · Clinical Infectious Diseases · doi:10.1086/324620 · Cited by 844 · cited 1×
“In a noncomparative study, voriconazole initially demonstrated promise of prophylaxis against Aspergillus infections as salvage or primary therapy in 116 patients with invasive aspergillosis.(183) Complete or partial response to therapy was demonstrated in 56 (48%) of 116 patients treated with voriconazole.”
BackgroundInvasive Aspergillosis Disease Spectrum, Treatment Practices, and Outcomes
Patterson, T. F., Kirkpatrick, W. R., White, M., Hiemenz, J. W., WINGARD, J. R., DUPONT, B., RINALDI, M. G., STEVENS, D. A., & Graybill, J. R. (2000) · Medicine · doi:10.1097/00005792-200007000-00006 · Cited by 791 · cited 1×
“successful treatment.(20) Thus, tools for early diagnosis, preventive strategies, and new agents for treatment of the disease are needed to reduce overall mortality in patients with invasive aspergillosis.”
BackgroundKuse, E.-R., Chetchotisakd, P., da Cunha, C. A., Ruhnke, M., Barrios, C., Raghunadharao, D., Sekhon, J. S., Freire, A., Ramasubramanian, V., Demeyer, I., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60605-9 · Cited by 692
Self-citationTrick, W. E., Fridkin, S. K., Edwards, J. R., Hajjeh, R. A., Gaynes, R. P., & Hospitals, T. N. N. I. S. S. (2002) · Clinical Infectious Diseases · doi:10.1086/342300 · Cited by 660
Combination antifungal therapy
Johnson, M. D., MacDougall, C., Ostrosky-Zeichner, L., Perfect, J. R., & Rex, J. H. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.3.693-715.2004 · Cited by 541
Self-citationKullberg, B., Sobel, J., Ruhnke, M., Pappas, P., Viscoli, C., Rex, J., Cleary, J., Rubinstein, E., Church, L., Brown, J., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67490-9 · Cited by 521
Rex, J. H., Pappas, P. G., Karchmer, A. W., Sobel, J., Edwards, J. E., Hadley, S., Brass, C., Vazquez, J. A., Chapman, S. W., Horowitz, H. W., et al. (2003) · Clinical Infectious Diseases · doi:10.1086/374850 · Cited by 495
Fluconazole prophylaxis prevents intra-abdominal candidiasis in high-risk surgical patients
Eggimann, P., Francioli, P., Bille, J., Schneider, R., Wu, M.-M., Chapuis, G., Chiolero, R., Pannatier, A., Schilling, J., Geroulanos, S., et al. (1999) · Critical Care Medicine · doi:10.1097/00003246-199906000-00019 · Cited by 414
Douglas, C. M., Foor, F., Marrinan, J. A., Morin, N., Nielsen, J. B., Dahl, A. M., Mazur, P., Baginsky, W., Li, W., & el-Sherbeini, M. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.26.12907 · Cited by 401
Nguyen, M. H. (1995) · Archives of Internal Medicine · doi:10.1001/archinte.1995.00430220087009 · Cited by 363
Ally, R., Schürmann, D., Kreisel, W., Carosi, G., Aguirrebengoa, K., Dupont, B., Hodges, M., Troke, P., Romero, A. J., & the Esophageal Candidiasis Study Group (2001) · Clinical Infectious Diseases · doi:10.1086/322653 · Cited by 331 · cited 6×
“Fluconazole 100 mg/day was compared with ketoconazole 200 mg/day for treatment of esophageal candidiasis in 169 patients with AIDS.141 Therapy was continued for 2 weeks after symptom resolution, for a maximum of 8 weeks.”
BackgroundInfluentialPfaller, M. A., Diekema, D. J., Jones, R. N., Messer, S. A., & Hollis, R. J. (2002) · Journal of Clinical Microbiology · doi:10.1128/jcm.40.3.852-856.2002 · Cited by 331
Boogaerts, M., Winston, D. J., Bow, E. J., Garber, G., Reboli, A. C., Schwarer, A. P., Novitzky, N., Boehme, A., Chwetzoff, E., De Beule, K., et al. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-135-6-200109180-00010 · Cited by 321
Echinocandins: a new class of antifungal
Denning, D. W. (2002) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkf045 · Cited by 300 · cited 2×
“The genes that encode the b-(1,3)-Dglucan synthase complex are FKS1 and FKS2.(216) Transcription of fungal cell wall proteins regulated by FKS2 is dependent on the enzyme calcineurin and the proteins regulated by FKS1 regulated by fungal cell turnover.”
BackgroundAttributable mortality of candidemia: a systematic review of matched cohort and case-control studies
Falagas, M. E., Apostolou, K. E., & Pappas, V. D. (2006) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-006-0159-2 · Cited by 294
Arathoon, E. G., Gotuzzo, E., Noriega, L. M., Berman, R. S., DiNubile, M. J., & Sable, C. A. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.2.451-457.2002 · Cited by 254
Phillips, P., Shafran, S., Garber, G., Rotstein, C., Smaill, F., Fong, I., Salit, I., Miller, M., Williams, K., Conly, J. M., et al. (1997) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/bf01726360 · Cited by 221
Ostrosky-Zeichner, L., Kontoyiannis, D., Raffalli, J., Mullane, K. M., Vazquez, J., Anaissie, E. J., Lipton, J., Jacobs, P., Rensburg, J. H. J., Rex, J. H., et al. (2005) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-005-0024-8 · Cited by 189
Self-citationPaphitou, N. I., Ostrosky-Zeichner, L., & Rex, J. H. (2005) · Medical Mycology · doi:10.1080/13693780410001731619 · Cited by 179 · cited 2×
“Prolonged stay in the intensive care unit (ICU), placement of central venous catheters, prolonged treatment with broad-spectrum antibiotics, receipt of parenteral nutrition, recent surgery (particularly intraabdominal), hemodialysis, and a diagnosis of diabetes mellitus or pancreatitis have been identified as risk fac…”
BackgroundSelf-citationSafety and tolerability of caspofungin acetate in the treatment of fungal infections
Sable, C. A., Nguyen, B. T., Chodakewitz, J. A., & DiNubile, M. J. (2002) · Transplant Infectious Disease · doi:10.1034/j.1399-3062.2002.01004.x · Cited by 148 · cited 1×
“In a collective safety evaluation of caspofungin clinical trials, the most common drug-related adverse events were fever (12–26%) and phlebitis at the infusion site (12–18%).(237) In addition, the most common laboratory abnormalities were increased aspartate aminotransferase (AST), alanine aminotransferase (ALT), and…”
BackgroundThe yeast cell-wall salvage pathway
Popolo, L., Gualtieri, T., & Ragni, E. (2001) · Medical Mycology · doi:10.1080/mmy.39.1.111.121 · Cited by 142
Laine, L., Dretler, R. H., Conteas, C. N., Tuazon, C., Koster, F. M., Sattler, F., Squires, K., & Islam, M. Z. (1992) · Annals of Internal Medicine · doi:10.7326/0003-4819-117-8-655 · Cited by 131 · cited 6×
“Fluconazole 100 mg/day was compared with ketoconazole 200 mg/day for treatment of esophageal candidiasis in 169 patients with AIDS.141 Therapy was continued for 2 weeks after symptom resolution, for a maximum of 8 weeks.”
MethodInfluentialBarbaro, G., Barbarini, G., Calderon, W., Grisorio, B., Alcini, P., & Di Lorenzo, G. (1996) · Gastroenterology · doi:10.1053/gast.1996.v111.pm8898629 · Cited by 78 · cited 6×
“Fluconazole 100 mg/day was compared with ketoconazole 200 mg/day for treatment of esophageal candidiasis in 169 patients with AIDS.141 Therapy was continued for 2 weeks after symptom resolution, for a maximum of 8 weeks.”
ResultInfluential
Cited by
Natural products: A continuing source of novel drug leads
Cragg, G. M., & Newman, D. J. (2013) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2013.02.008 · Cited by 2,906
Triazole Antifungal Agents in Invasive Fungal Infections: A Comparative Review
Lass-Flörl, C. (2011) · Drugs · doi:10.2165/11596540-000000000-00000 · Cited by 270
Management of invasive fungal infections: a role for polyenes
Chandrasekar, P. (2011) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkq479 · Cited by 100
Zarember, K. A., Cruz, A. R., Huang, C.-Y., & Gallin, J. I. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01547-08 · Cited by 78
“Prophylaxis using antifungal drugs has markedly reduced the occurrence of these infections (8, 19, 23, 24); however, mortality for aspergillosis remains high (17).”
BackgroundAntifungals in Clinical Use and the Pipeline
Johnson, M. D. (2021) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2021.03.005 · Cited by 35
Self-citation
Metadata
- Authors
- Mohr, J., Johnson, M., Cooper, T., Lewis, J. S., & Ostrosky‐Zeichner, L.
- Venue
- Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Publisher
- Wiley
- Published
- 2008-05
- Volume
- 28
- Issue
- 5
- Pages
- 614-645
- ISSN
- 0277-0008 (ISSN-L)
- 1875-9114
- OpenAlex
- W2115179464
- Cited by
- 84
- References
- 35
- FWCI
- 4.41
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.